Verastem announces R&D update for VS-7375 KRAS inhibitor
Verastem hosted an R&D update call discussing the KRAS G12D inhibitor VS-7375. This information is relevant for investors assessing the company's potential pipeline opportunities in the oncology space.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day